Добірка наукової літератури з теми "Kinase inhibitor treatments"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Kinase inhibitor treatments".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Kinase inhibitor treatments"
Gäbler, Karoline, Catherine Rolvering, Valérie Palissot, Guy J. Berchem, Iris Behrmann, and Claude Haan. "Combined Inhibition of Janus and Aurora Kinase Effectively Suppresses Proliferation of JAK2 V617F-expressing Cells." Blood 118, no. 21 (November 18, 2011): 2813. http://dx.doi.org/10.1182/blood.v118.21.2813.2813.
Повний текст джерелаLin, Yipeng. "Kinase inhibitor therapies for Chronic lymphocytic leukaemia (CLL): SYK, BTK and PI3K inhibitors." Highlights in Science, Engineering and Technology 19 (November 17, 2022): 30–35. http://dx.doi.org/10.54097/hset.v19i.2691.
Повний текст джерелаTokuyama, Michio, and Tomotaka Mabuchi. "New Treatment Addressing the Pathogenesis of Psoriasis." International Journal of Molecular Sciences 21, no. 20 (October 11, 2020): 7488. http://dx.doi.org/10.3390/ijms21207488.
Повний текст джерелаAhmadu, Augustine A., Claire Delehouzé, Anas Haruna, Lukman Mustapha, Bilqis A. Lawal, Aniefiok Udobre, Blandine Baratte, et al. "Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor." Molecules 26, no. 15 (July 29, 2021): 4599. http://dx.doi.org/10.3390/molecules26154599.
Повний текст джерелаFlis, Sylwia, Ewelina Bratek, Tomasz Chojnacki, Marlena Piskorek, and Tomasz Skorski. "Simultaneous Inhibition of BCR-ABL1 Tyrosine Kinase and PAK1/2 Serine/Threonine Kinase Exerts Synergistic Effect against Chronic Myeloid Leukemia Cells." Cancers 11, no. 10 (October 12, 2019): 1544. http://dx.doi.org/10.3390/cancers11101544.
Повний текст джерелаGrisouard, Jean, Elisa Bouillet, Katharina Timper, Tanja Radimerski, Kaethi Dembinski, Daniel M. Frey, Ralph Peterli, et al. "Both inflammatory and classical lipolytic pathways are involved in lipopolysaccharide-induced lipolysis in human adipocytes." Innate Immunity 18, no. 1 (November 18, 2010): 25–34. http://dx.doi.org/10.1177/1753425910386632.
Повний текст джерелаOkabe, Seiichi, Tetsuzo Tauchi, Seiichiro Katagiri, Yuko Tanaka, and Kazuma Ohyashiki. "Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells." Blood 120, no. 21 (November 16, 2012): 3737. http://dx.doi.org/10.1182/blood.v120.21.3737.3737.
Повний текст джерелаBoland, Sonja, Véronique Bonvallot, Thierry Fournier, Armelle Baeza-Squiban, Michel Aubier, and Francelyne Marano. "Mechanisms of GM-CSF increase by diesel exhaust particles in human airway epithelial cells." American Journal of Physiology-Lung Cellular and Molecular Physiology 278, no. 1 (January 1, 2000): L25—L32. http://dx.doi.org/10.1152/ajplung.2000.278.1.l25.
Повний текст джерелаOsses, Nelson, and Enrique Brandan. "ECM is required for skeletal muscle differentiation independently of muscle regulatory factor expression." American Journal of Physiology-Cell Physiology 282, no. 2 (February 1, 2002): C383—C394. http://dx.doi.org/10.1152/ajpcell.00322.2001.
Повний текст джерелаBilodeau-Goeseels, Sylvie, Nora Magyara, and Coralie Collignon. "Characterization of the effects of metformin on porcine oocyte meiosis and on AMP-activated protein kinase activation in oocytes and cumulus cells." Zygote 22, no. 2 (April 12, 2013): 275–85. http://dx.doi.org/10.1017/s0967199413000075.
Повний текст джерелаДисертації з теми "Kinase inhibitor treatments"
Losson, Hélène. "Combinaisons de nouveaux inhibiteurs de désacétylase d’histones 6 avec des inhibiteurs de tyrosine kinase pour le traitement de la leucémie myéloïde chronique." Thesis, Université de Lorraine, 2020. http://www.theses.fr/2020LORR0003.
Повний текст джерелаBreakpoint cluster region-Abelson (BCR-ABL)+ chronic myeloid leukemia (CML) patients receive tyrosine kinase inhibitors (TKIs) such as imatinib as the first-line treatment; however, some patients develop resistances and severe adverse effects. Combination treatments, especially with histone deacetylase (HDAC)6 inhibitors (HDAC6i), appear as an attractive option to prevent TKI resistances considering the capacity of HDAC6i to downregulate BCR-ABL. Moreover, HDAC6 is implicated in protein degradation pathways, so that its inhibition combined with that of the proteasome could sensitize cells to TKIs. Thus, we hypothesized that HDAC6i combined to TKIs could be effective for CML treatment. In the first part, we compared the anti-CML effects of a HDAC6i identified in our laboratory, compound 7b, to the reference HDAC6i tubacin, in combination with imatinib. Results showed that the imatinib-7b combination generated stronger anti- CML effects than imatinib-tubacin. Especially, the imatinib-7b combination elicited a potent synergistic caspase- dependent apoptotic cell death and drastically reduced the proportion of cancer stem cells in K562 CML cells, whereas it only moderately impacted various healthy cell models. Ultimately, the imatinib-7b combination decreased more potently the colony forming capacities and tumor mass formation of CML cells in a semisolid methylcellulose medium and in xenografted zebrafishes, respectively, compared to each compound alone. Mechanistically, the combination induced BCR-ABL ubiquitination and downregulation leading to a dysregulation of multiple key proteins of its downstream pathways involved in CML proliferation and survival. Results tend to demonstrate that 7b could target the second site. In the second part, we initiated a study of a novel hydroxamate-based HDAC6i, MAKV-15, and preliminary results demonstrated it triggered BCR-ABL downregulation. Accordingly, in pre-treatment with bortezomib it sensitizes CML cells to imatinib leading to enhanced caspase-dependent apoptotic death in imatinib-sensitive and imatinib-resistant CML cells. Considering that HDAC6 is reported to possess two functional catalytic sites, we finally attempted to determine which catalytic site is targeted by these HDAC6i. Taken together, our results suggest that HDAC6i potentiate the effect of imatinib and could overcome TKI resistance in CML cells and therefore such combination may represent a promising therapeutic approach for CML patients
Shor, Audrey Cathryn. "Src kinase inhibitors for the treatment of sarcomas : cellular and molecular mechanisms of action." [Tampa, Fla] : University of South Florida, 2007. http://purl.fcla.edu/usf/dc/et/SFE0001906.
Повний текст джерелаZhang, Wen. "Identification of novel pyruvate dehydrogenase kinase 1 (PDK1) inhibitors for anticancer therapeutics." Thesis, University of Macau, 2018. http://umaclib3.umac.mo/record=b3953604.
Повний текст джерелаAlsfouk, Aisha. "Synthesis and biological evaluation of selective inhibitory kappa B kinase-alpha (IKKa) inhibitors for the treatment of prostate and pancreatic cancer." Thesis, University of Strathclyde, 2018. http://digitool.lib.strath.ac.uk:80/R/?func=dbin-jump-full&object_id=29272.
Повний текст джерелаD'Cunha, Ronilda Raymond. "Treatment strategies to reverse efflux transporter-mediated resistance to Tyrosine kinase inhibitors." Diss., University of Iowa, 2018. https://ir.uiowa.edu/etd/6563.
Повний текст джерелаPadi, Sathish K. R., Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra, and Andrew S. Kraft. "Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset." IMPACT JOURNALS LLC, 2017. http://hdl.handle.net/10150/624055.
Повний текст джерелаMcIntyre, Neil A. "Synthesis of ring-constrained thiazolylpyrimidines : inhibitors of cyclin-dependent kinases." Thesis, University of St Andrews, 2006. http://hdl.handle.net/10023/353.
Повний текст джерелаHaaning, Kelsey L. "Deletion of the phosphoinositide-3-kinase RhoGAP domain to assess inhibition of Staphylococcus aureus infection." Virtual Press, 2008. http://liblink.bsu.edu/uhtbin/catkey/1398713.
Повний текст джерелаDepartment of Biology
Deininger, Michael Werner Nikolaus. "STI571, a novel tyrosine kinase inhibitor : pre-clinical evaluation and application to identify downstream targets of BCR-ABL." Thesis, Imperial College London, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.325912.
Повний текст джерелаTrousil, Sebastian. "Choline kinase inhibition as a treatment strategy of cancers with deregulated lipid metabolism." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/25146.
Повний текст джерелаКниги з теми "Kinase inhibitor treatments"
Gaestel, Matthias, and K. Asadullah. Kinase targets and inhibitors in inflammation, 2007. Trivandrum, India: Transworld Research Network, 2007.
Знайти повний текст джерелаMüller, Gerhard, and Bert Klebl. Protein kinases as drug targets. Weinheim: Wiley-VCH, 2011.
Знайти повний текст джерелаHoughton, Peter J., and V. A. Polunovskiĭ. mTOR pathway and mTOR inhibitors in cancer therapy. New York: Humana Press, 2010.
Знайти повний текст джерелаservice), SpringerLink (Online, ed. Small Molecules in Oncology. Berlin, Heidelberg: Springer-Verlag Berlin Heidelberg, 2010.
Знайти повний текст джерелаFleischmann, Roy. Signalling pathway inhibitors. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0081.
Повний текст джерелаMease, Philip. Biologic treatments for psoriatic arthritis apart from TNF inhibition. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198737582.003.0030.
Повний текст джерелаMcCormick, Frank, and Doriano Fabbro. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2010.
Знайти повний текст джерелаMcCormick, Frank. Protein Tyrosine Kinases: From Inhibitors to Useful Drugs. Humana Press, 2005.
Знайти повний текст джерелаMannhold, Raimund, Hugo Kubinyi, Michael Hamacher, Bert Klebl, and Gerhard Müller. Protein Kinases As Drug Targets. Wiley & Sons, Incorporated, John, 2011.
Знайти повний текст джерелаCyclin Dependent Kinase 5 Cdk5. Springer, 2008.
Знайти повний текст джерелаЧастини книг з теми "Kinase inhibitor treatments"
Colinge, Jacques, Uwe Rix, Keiryn L. Bennett, and Giulio Superti-Furga. "Systems Biology Analysis of Kinase Inhibitor Protein Target Profiles in Leukemia Treatments." In Information Processign in Cells and Tissues, 62–66. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-28792-3_9.
Повний текст джерелаHeron, Courtney E., Lindsay C. Strowd, and Steven R. Feldman. "Janus Kinase (JAK) Inhibitors." In Handbook of Systemic Drug Treatment in Dermatology, 170–76. 3rd ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-25.
Повний текст джерелаRoden, Dylan F., Jennifer M. Johnson, Petr Szturz, Paolo Bossi, and Athanassios Argiris. "New and Promising Targeted Therapies in First and Second-Line Settings." In Critical Issues in Head and Neck Oncology, 277–96. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_18.
Повний текст джерелаRadich, Jerald, and Daniel Egan. "Goals of CML Treatment in the Tyrosine Kinase Inhibitor Era." In Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia, 53–67. Tokyo: Springer Japan, 2016. http://dx.doi.org/10.1007/978-4-431-55714-2_4.
Повний текст джерелаGopalakrishna, R., U. Gundimeda, and Z. Chen. "Vitamin E Succinate Inhibits Protein Kinase C: Correlation with its Unique Inhibitory Effects on Cell Growth and Transformation." In Nutrients in Cancer Prevention and Treatment, 21–37. Totowa, NJ: Humana Press, 1995. http://dx.doi.org/10.1007/978-1-4612-0237-0_2.
Повний текст джерелаHughes, Timothy P., David M. Ross, and Junia V. Melo. "Challenges of Treatment: Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia." In Handbook of Chronic Myeloid Leukemia, 53–65. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08350-6_5.
Повний текст джерелаHeron, Nicola. "From Discovery to Clinic: Aurora Kinase Inhibitors as Novel Treatments for Cancer." In Protein Kinases as Drug Targets, 195–228. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527633470.ch7.
Повний текст джерелаLang, Gabriele E. "Treatment of Diabetic Retinopathy with Protein Kinase C Subtype &Bg;; Inhibitor." In Developments in Ophthalmology, 157–65. Basel: KARGER, 2007. http://dx.doi.org/10.1159/000098506.
Повний текст джерелаWilson, S. "The Role of Tyrosine Kinase Inhibitors in the Treatment of ALL." In New Agents for the Treatment of Acute Lymphoblastic Leukemia, 203–19. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-8459-3_11.
Повний текст джерелаDadu, Ramona, Mimi N. Hu, Elizabeth G. Grubbs, and Robert F. Gagel. "Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma." In Medullary Thyroid Carcinoma, 227–49. Cham: Springer International Publishing, 2015. http://dx.doi.org/10.1007/978-3-319-22542-5_11.
Повний текст джерелаТези доповідей конференцій з теми "Kinase inhibitor treatments"
Polo, Maria Laura, Marina Riggio, Victoria Wargon, Sebastian Giulianelli, Silvia I. Vanzulli, Claudia Lanari, and Virginia Novaro. "Abstract 1319: Early tumor regression after endocrine and kinase inhibitor treatments in mammary carcinomas with different hormonal requirements." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-1319.
Повний текст джерелаSantos, Tabata M., Elaine C. Campos, Renato F. Riguetti, Leandro N. Camargo, Silvia Fukuzaki, Bianca G. Rezende, Beatriz M. Saraiva-Romanholo, et al. "Effect of anti-IL17 and/or Rho-kinase inhibitor treatments on vascular remodelling in an asthma model in mice." In ERS International Congress 2019 abstracts. European Respiratory Society, 2019. http://dx.doi.org/10.1183/13993003.congress-2019.pa4219.
Повний текст джерелаSwearingen, Amanda E. D. Van, Maria J. Sambade, Marni B. Siegel, Shivani Sud, Samantha M. Bevill, Brian T. Golitz, Ryan E. Bash, et al. "Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models." In Abstracts: AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer; January 4-7, 2017; San Diego, CA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-8514.synthleth-a03.
Повний текст джерелаKheraldine, Hadeel, Ishita Gupta, Farhan Cyprian, Semir Vranic, and Ala-Eddin Al Moustafa. "The Combination of Dasatinib and PD L1 inhibitor prevents the progression of epithelial mesenchymal transition and dramatically blocks cell invasion of HER2 positive breast cancer cells." In Qatar University Annual Research Forum & Exhibition. Qatar University Press, 2021. http://dx.doi.org/10.29117/quarfe.2021.0105.
Повний текст джерелаHenzler, Tanja, Stefanie Pohl, Nicole Schneiderhan-Mara, Stefanie Rimmele, April Livengood, Robert Kovelman, and Thomas Herget. "Abstract LB-227: Receptor tyrosine kinase phosphorylation: Simultaneous detection of 10 kinases upon inhibitor treatment." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-lb-227.
Повний текст джерелаNomanbhoy, Tyzoon K., Heidi E. Brown, Jiangyue Wu, Subha Vogeti, Arwin Aban, Wendy Grant, Alemayehu Senait, Shuzhen Wu, Christa Dias, and Geeta Sharma. "Abstract B23: Chemoproteomic profiling of native kinases during the treatment of cells with kinase inhibitors." In Abstracts: Fourth AACR International Conference on Frontiers in Basic Cancer Research; October 23-26, 2015; Philadelphia, PA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.fbcr15-b23.
Повний текст джерелаYamaguchi, A., H. Azuma, S. Sekizaki, K. Tanoue, and H. Yamazaki. "ROLE OF MEMBRANE DEPOLARIZATION IN PLATELET ACTIVATION INDUCED BY THROMBIN." In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1644473.
Повний текст джерелаBjerregaard, Anne-Mette, Michael V. Grandal, Camilla Frohlich, Trine Lindsted, Christina Egebjerg, Ivan D. Horac, Michael Kragh, and Mikkel W. Pedersen. "Abstract 5455: Surface accumulation of receptor tyrosine kinases upon treatment with tyrosine kinase inhibitors and resulting enhancement of activity upon treatment cessation." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5455.
Повний текст джерелаLee, Kwangho, Hyoung Rae Kim, Sung Yun Cho, Hee Jung Jung, Jae D. Ha, Chang-Soo Yun, Pilho Kim, Chi Hoon Park, and Chong Ock Lee. "Abstract A284: Anaplastic lymphoma kinase (ALK) inhibitors for cancer treatment." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-a284.
Повний текст джерелаKowalczyk, Piotr, Paulina Wegrzyn, Przemyslaw Zawadzki, Edyta Palacz, Ewa Trebacz, Katarzyna Wiklik, Mariusz Milik, Adrian Zarebski, Karolina Krawczynska, and Krzysztof Brzózka. "Abstract 2160: Development of selective MELK kinase inhibitors for cancer treatments." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2160.
Повний текст джерелаЗвіти організацій з теми "Kinase inhibitor treatments"
Zheng, Jiaxi, and Haihua Yang. Clinical Benefits of Immune Checkpoint Inhibitors and Predictive Value of Tumor Mutation Burden in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0008.
Повний текст джерелаReiss, Michael. Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2002. http://dx.doi.org/10.21236/ada408030.
Повний текст джерелаReise, Michael. TGF-beta Type I Receptor Kinase Inhibitors - A Novel Treatment for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, June 2003. http://dx.doi.org/10.21236/ada416442.
Повний текст джерелаSong, Yaowen, Shuiyu Lin, Jun Chen, Silu Ding, and Jun Dang. First-line treatment with TKI plus brain radiotherapy vs TKI alone in EGFR-mutated non-small-cell lung cancer with brain metastases: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2023. http://dx.doi.org/10.37766/inplasy2023.1.0013.
Повний текст джерелаEdelman, Arthur. Study of Inhibitors of Neu and Related Tyrosine-Specific Protein Kinases: Implications for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1998. http://dx.doi.org/10.21236/ada360940.
Повний текст джерелаEdelman, Arthur. Study of Inhibitors of Neu and Related Tyrosine-Specific Protein Kinases: Implications for the Treatment of Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1997. http://dx.doi.org/10.21236/ada338938.
Повний текст джерелаPhilosoph-Hadas, Sonia, Peter Kaufman, Shimon Meir, and Abraham Halevy. Signal Transduction Pathway of Hormonal Action in Control and Regulation of the Gravitropic Response of Cut Flowering Stems during Storage and Transport. United States Department of Agriculture, October 1999. http://dx.doi.org/10.32747/1999.7695838.bard.
Повний текст джерелаEhrlich, Marcelo, John S. Parker, and Terence S. Dermody. Development of a Plasmid-Based Reverse Genetics System for the Bluetongue and Epizootic Hemorrhagic Disease Viruses to Allow a Comparative Characterization of the Function of the NS3 Viroporin in Viral Egress. United States Department of Agriculture, September 2013. http://dx.doi.org/10.32747/2013.7699840.bard.
Повний текст джерела